Teriparatide 600 mcg
| Product Overview | |
| Generic Name | Teriparatide 600 mcg |
| Brand Name(s) | Forteo, Forsteo, Biosimilars... |
| Form | PFS & Vial, solution for subcutaneous injection |
| Strength | 600 mcg per 2.4 mL pen (250 mcg/mL; delivers 28 daily doses of 20 mcg) |
| Therapeutic Class | Recombinant N-terminal PTH (PTH 1‑34) analogue |
| ATC Code | H05AA02 |
| Manufacturing & Regulatory | |
| Manufacturer | Eli Lilly, Cipla |
| Country | USA, India |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Not publicly disclosed |
| COFEPRIS | Under Registration (2025) |
| Free Sale Certificate | Available per batch upon request |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 36 months |
| Storage | Store refrigerated at 2–8 °C; minimize time out of refrigerator |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
| SDS | Upon Request, not publicly posted |
| CTD Summary | Full CTD proprietary; available under commercial agreement/license |
Description
Indications & Usage: Teriparatide is indicated for treatment of osteoporosis in postmenopausal women at high fracture risk, increasing bone mass in men, and glucocorticoid-induced osteoporosis. Administered subcutaneously once daily up to 2 years. It stimulates new bone formation via PTH receptor activation.
